Trastuzumab deruxtecan is a HER2-directed ADC, consisting of trastuzumab, a humanized anti-HER2 antibody linked to a topoisomerase I inhibitor payload, approved for use in advanced HER2-positive breast cancer (Cortes et al., 2022). This evidence concerns the gene ERBB2 and breast carcinoma.